市场概况
早盘三大指数集体高开，随后全天震荡走高，科技股集体反弹，个股普涨。前期下高位下杀股上演地天板，短线人气回升，盘中RCS、医药、新能源车、农业等板块反复活跃，特高压、数据中心、充电桩等新基建板块表现强势，券商板块因消息刺激异动拉升。盘面上看，RCS、新能源车等板块涨幅居前，仅有1个板块收绿。截至收盘，沪指涨1.59%，报收2827点；深成指涨2.47%，报收10475点；创业板指涨3.24%，报收1985点。
消息面
- 科技部社会发展科技司司长吴远彬表示，目前有三个疫苗获批进入临床试验，其中腺病毒载体疫苗已于3月底完成一期临床试验，并于4月9日开始招募二期临床试验者，这是全球第一个启动二期临床试验的新冠疫苗品种。
- 分众传媒2020年第一季度业绩预告，归属于上市公司股东的净利润2800万元-4200万元，比上年同期下降87.66%-91.77%。报告期内，受新冠肺炎疫情影响，国内广告市场需求较去年同期有较大幅度下滑，致使公司营业收入同比减少；鉴于全国各地实施较为严格的疫情防控措施，报告期内影院暂停营业（目前尚未恢复），部分城市、社区及道路采取封闭管理（目前已恢复），致使公司在部分城市和地区广告的正常发布受限。
欧菲光：预计一季度净利润为1.2亿-1.8亿元，去年同期亏损2.57亿元。公司各项业务进展顺利，订单稳步释放，高端产品占比提高，核心业务产品营业收入和出货量均实现较快增长
交易点评
整体来看尽管今日行情有所好转，但并未形成新的热点主线，以及消息面和经济数据存在诸多不确定性，短期反弹可保持中性态度。
资金流向
行业板块资金流向方面，资金流入居前的板块是电子信息、电子器件和有色金属行业，资金流出居前的板块是医疗器械、农药化肥和建筑建材行业。 沪股通及深股通方面，沪股通资金净流入58.45亿元，当日余额461.55元；深股通资金净流入106.67亿元，当日余额413.33亿元。
截止收盘
| 开盘 | 收盘 | 涨跌幅% | 成交额（亿元） | |
| 上证指数 | 2794.80 | 2827.28 | 1.59 | 2236.06 |
| 深证成指 | 10300.96 | 10475.71 | 2.47 | 3657.22 |
| 沪深300 | 3777.83 | 3825.70 | 1.93 | 1706.13 |
| 创业板 | 1937.29 | 1985.43 | 3.24 | 1232.49 |
Disclosure: Interactive Brokers
Information posted on IBKR Traders’ Insight that is provided by third-parties and not by Interactive Brokers does NOT constitute a recommendation by Interactive Brokers that you should contract for the services of that third party. Third-party participants who contribute to IBKR Traders’ Insight are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.
This material is from Guosen Securities Co., Ltd and is being posted with permission from Guosen Securities Co., Ltd. The views expressed in this material are solely those of the author and/or Guosen Securities Co., Ltd and IBKR is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to sell or the solicitation of an offer to buy any security. To the extent that this material discusses general market activity, industry or sector trends or other broad based economic or political conditions, it should not be construed as research or investment advice. To the extent that it includes references to specific securities, commodities, currencies, or other instruments, those references do not constitute a recommendation to buy, sell or hold such security. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.
In accordance with EU regulation: The statements in this document shall not be considered as an objective or independent explanation of the matters. Please note that this document (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and (b) is not subject to any prohibition on dealing ahead of the dissemination or publication of investment research.
Any trading symbols displayed are for illustrative purposes only and are not intended to portray recommendations.
Disclosure: Chinese Translation
这篇文章已被翻译成中文。如英文版本和中文版本之间有任何不一致，以英文版本为准。该文章中的分析仅为提供信息，不是也不应该被视为推销或招揽购买任何证券。文章中讨论的一般市场活动、行业或领域趋势、或其它基于广泛的经济或政治条件的内容，不应被解释为研究结果或投资建议。讨论中提及包括的特定证券、商品、货币、或其它产品均不构成IB推荐购买，出售或持有此类投资的建议。本材料不是也不意图针对个别客户的特定财务条件、投资目标或要求。在根据本材料采取行动之前，您应该考虑是否适合您的具体情况，并在必要时寻求专业建议。
盈透交易员睿智中提供的内容（包括文章和评论）仅作为资讯用途。发布的内容并不代表盈透证券建议您或您的客户联系独立顾问或对冲基金以期获取其服务或投资其产品，也不代表建议您联系在盈透交易员睿智发布文章或向顾问、对冲基金投资的相关人士。在盈透交易员睿智中发布文章的顾问、对冲基金或其他分析师均独立于盈透证券，盈透证券不会对这些顾问、对冲基金或其他人士的过往或将来表现，或其提供的信息之准确性做出任何声明或担保。盈透证券不会进行“适宜性评估”来确保顾问、对冲基金或其他参与方的交易适合于您。
发布内容中提及的证券或其他金融产品并非适合所有投资者。发布的内容并未从您的投资目标、财务状况或需求出发，并不旨在向您推荐任何证券、金融产品或策略。过往业绩并不代表将来表现，如有需要，请咨询相关人士获取专业的建议。
盈透或其分支机构的雇员所发布的任何信息均基于公认的真实可信的信息。然而，盈透或其分支机构无法保证信息的完整性、准确性和适当性。盈透不对任何金融产品其过去或将来的表现作出任何声明或担保。交易员睿智中发布的文章并不代表盈透认为任何特定金融产品或交易策略适合您。
